Novartis AG (NYSE: NVS)
Drug Manufacturers - General · Basel, Switzerland · Founded 1996
- Market capitalization: $220.0 billion
- Annual revenue: $46.0 billion
- Net income: $12.0 billion
- Employees: 78,000
- Sector: Healthcare
- Headquarters: Basel, Switzerland
- Founded: 1996
Source: Statvoo company profile for Novartis AG. Browse all 500+ companies
Novartis is a top-five global pharmaceutical company headquartered in Basel, Switzerland, with about $46 billion in annual revenue. The company refocused as a pure-play innovative medicines company after spinning off its generics division Sandoz in October 2023. Key franchises include Entresto (heart failure, $6B+ in sales), Cosentyx (immunology), Kisqali (breast cancer), and Pluvicto (prostate cancer). Novartis has one of the broadest pipelines in pharma with over 100 projects in clinical development.
Pure innovative medicines — Novartis discovers, develops, and commercializes patented drugs across cardiovascular, immunology, neuroscience, oncology, and hematology. The Sandoz spinoff removed the lower-margin generics business, improving the overall margin profile. U.S. sales account for roughly 38% of revenue, with Europe and emerging markets providing geographic diversification.
Novartis was formed in 1996 from the merger of Ciba-Geigy and Sandoz — two Swiss chemical and pharmaceutical companies with roots in the 1800s. The company acquired Alcon (eye care) in 2011 and then spun it off in 2019. CEO Vas Narasimhan, who took over in 2018, has been reshaping the portfolio through the Sandoz spinoff and targeted acquisitions like MorphoSys ($2.7B, 2024).
| Market Capitalization | $220.0B |
| Annual Revenue | $46.0B |
| Net Income | $12.0B |
| Profit Margin | 26% |
| Revenue per Employee | $589744K |
| Stock Exchange | NYSE |
| Ticker Symbol | NVS |
Financial data is approximate and based on most recent annual filings.
Novartis' gene therapy Zolgensma, priced at $2.1 million per dose, was the most expensive drug in the world when it launched in 2019. The company's campus in Basel is designed by some of the world's most famous architects, including Frank Gehry and Tadao Ando. Novartis was one of the first pharma companies to use AI extensively in drug discovery, partnering with Microsoft and building internal capabilities.
Post-Sandoz, Novartis is a cleaner growth story with improving margins. Entresto and Kisqali are strong growth drivers, and the pipeline depth provides multiple shots on goal. Narasimhan's strategic clarity is paying off.
What is Novartis AG's revenue?
Novartis AG generates approximately $46.0 billion in annual revenue.
How many employees does Novartis AG have?
Novartis AG employs approximately 78,000 people worldwide.
What is Novartis AG's market cap?
Novartis AG (NVS) has a market capitalization of approximately $220.0 billion on the NYSE.
When was Novartis AG founded?
Novartis AG was founded in 1996 and is headquartered in Basel, Switzerland.
Who is the CEO of Novartis AG?
Vas Narasimhan is the current CEO of Novartis AG.
What is Novartis AG's website?
Novartis AG's official website is novartis.com.
| CEO | Vas Narasimhan |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Founded | 1996 |
| HQ | Basel |
| Country | Switzerland |
| Website | novartis.com |
See traffic, security, and technical data for Novartis AG's website:
📊 novartis.com stats 📋 WHOIS 🌐 DNS 🔒 SSL